

Helpful Hints for Ordering the clonoSEQ® Assay

Questions? Contact Adaptive Clinical Services
P: 888 552 8988 | F: 866 623 4408
clinicalservices@adaptivebiotech.com

clonoSEQ.com



SPECIMEN PREPARATION

Review Requirements

- ✓ Guidance for sending specimens can be found on clonoSEQ.com.

Provide Ample Material

- ✓ If ordering more than one Clonality Test (i.e. B-cell **and** T-cell*) include double the sample material requested in the Specimen Requirements document.

Label w/ 2 Unique Identifiers

- ✓ Each specimen must be labeled with **2 unique patient identifiers**. These identifiers must match the patient information you entered on the **Test Requisition Form (TRF)**.



TEST REQUISITION FORM (TRF)

Complete



✓ FILL OUT SPECIMEN FIELDS

Fully complete the Specimen Information section of the TRF, especially the "collection date." These fields are not required to save and print a TRF, but **they are required prior to sending a specimen**.

Verify



✓ VERIFY INSURANCE INFORMATION HASN'T CHANGED

If you previously provided a patient's insurance details, they will automatically appear when you start a new TRF. Verify this information is correct before saving and printing the TRF.

Sign



✓ PROVIDE SIGNED & DATED TRF

Completed TRF must be sent to Adaptive before a sample can be processed.

Request



✓ PROVIDE COMPLETE PATHOLOGY REPORT (ID SPECIMENS ONLY)

If you would like assistance from Adaptive to request a pathology sample, **send a copy of the patient's complete pathology report with the signed and dated TRF** to Clinical Services.



Required fields are highlighted in yellow on a printed TRF as a reminder to complete them before sending. **TRFs with missing or incorrect information will delay ordering and the delivery of patient results.**

clonoSEQ®

Copyright © 2020 Adaptive Biotechnologies Corp.
All rights reserved.
PM-US-cSEQ-0112-1 | MRK-00195-2

*T-cell testing is available via Adaptive's CLIA-validated LDT service and has not been cleared or approved by the FDA.

clonoSEQ® is available as an FDA-cleared *in vitro* diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.

Adaptive
biotechnologies®